Oruka Therapeutics (NASDAQ:ORKA) Shares Up 5.6% - Here's Why

Key Points

• Shares of Oruka Therapeutics jumped 5.6% to about $46.27 (intraday high $47.07) on Thursday, despite trading volume of ~149,968 shares — roughly a 70% decline from the average session volume.
• Analysts have grown more bullish, with multiple firms initiating or raising targets (Piper Sandler $75, BTIG $73, Guggenheim $60, Barclays $50), resulting in a consensus rating of Moderate Buy and an average price target of $59.60.
• Oruka beat quarterly estimates, reporting EPS of ($0.45) versus consensus ($0.61) (a $0.16 beat), while insiders have sold ~23,765 shares (~$849,575) over the past three months and currently own about 24.7% of the stock.

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) shot up 5.6% during trading on Thursday . The stock traded as high as $47.07 and last traded at $46.2690. 149,968 shares traded hands during mid-day trading, a decline of 70% from the average session volume of 492,638 shares. The stock had previously closed at $43.81.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Piper Sandler initiated coverage on shares of Oruka Therapeutics in a report on Thursday, December 18th. They set an "overweight" rating and a $75.00 price target for the company. Wall Street Zen raised shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, March 16th. BTIG Research reissued a "buy" rating and set a $73.00 target price on shares of Oruka Therapeutics in a research note on Friday, March 13th. Barclays boosted their target price on shares of Oruka Therapeutics from $48.00 to $50.00 and gave the company an "overweight" rating in a report on Friday, March 13th. Finally, Guggenheim reaffirmed a "buy" rating and set a $60.00 price target on shares of Oruka Therapeutics in a research report on Friday, March 13th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Oruka Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $59.60.

Oruka Therapeutics Price Performance

The stock has a fifty day simple moving average of $34.86 and a two-hundred day simple moving average of $29.02. The firm has a market capitalization of $2.30 billion, a P/E ratio of -24.92 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.61) by $0.16. As a group, sell-side analysts expect that Oruka Therapeutics, Inc. will post -3.41 EPS for the current fiscal year.

Insider Buying and Selling at Oruka Therapeutics

In other news, CEO Lawrence Otto Klein sold 1,729 shares of the company's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $71,407.70. Following the transaction, the chief executive officer owned 927,309 shares in the company, valued at approximately $38,297,861.70. This represents a 0.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Joana Goncalves sold 7,641 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $40.91, for a total transaction of $312,593.31. Following the transaction, the insider directly owned 33,377 shares in the company, valued at $1,365,453.07. This trade represents a 18.63% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 23,765 shares of company stock worth $849,575. 24.69% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc acquired a new stake in Oruka Therapeutics in the second quarter valued at approximately $28,000. Ameritas Investment Partners Inc. acquired a new position in shares of Oruka Therapeutics during the second quarter worth approximately $31,000. BNP Paribas Financial Markets lifted its holdings in shares of Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock worth $31,000 after purchasing an additional 2,306 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock worth $34,000 after purchasing an additional 365 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in Oruka Therapeutics in the 4th quarter valued at $37,000. 56.44% of the stock is owned by institutional investors and hedge funds.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.